692 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by FourThought Financial Partners LLC

FourThought Financial Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 692 shares of the pharmaceutical company’s stock, valued at approximately $279,000.

A number of other institutional investors have also recently added to or reduced their stakes in VRTX. Arkadios Wealth Advisors acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth approximately $312,000. Traynor Capital Management Inc. acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at $235,000. Integrated Advisors Network LLC raised its stake in shares of Vertex Pharmaceuticals by 11.3% during the third quarter. Integrated Advisors Network LLC now owns 3,753 shares of the pharmaceutical company’s stock valued at $1,746,000 after purchasing an additional 381 shares in the last quarter. Fidelis Capital Partners LLC grew its position in Vertex Pharmaceuticals by 5.5% in the 3rd quarter. Fidelis Capital Partners LLC now owns 5,465 shares of the pharmaceutical company’s stock valued at $2,569,000 after buying an additional 285 shares in the last quarter. Finally, Highview Capital Management LLC DE increased its stake in Vertex Pharmaceuticals by 2.4% during the 3rd quarter. Highview Capital Management LLC DE now owns 5,669 shares of the pharmaceutical company’s stock valued at $2,637,000 after buying an additional 134 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on VRTX shares. Piper Sandler reduced their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target for the company. in a research note on Thursday, January 30th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and upped their price objective for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Trading Down 0.3 %

NASDAQ:VRTX opened at $479.10 on Thursday. The stock has a market cap of $123.03 billion, a PE ratio of -217.77, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The stock’s 50-day moving average is $437.18 and its two-hundred day moving average is $460.90.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.